Dopamine transporter (DAT) function is altered by many neurodegenerative diseases. For instance, in Parkinson disease DAT density has been shown to decrease in early disease and to play a role in the occurrence of motor complications. DAT is thus an important imaging target with potential therapeutic relevance in humans and animal models of disease. The PET DAT marker 11 Cmethylphenidate is commonly used to quantify DAT function. Here we investigate the characteristics of the 11 C-methylphenidate-derived quantification of DAT in rodents using the 6-hydroxydopamine Parkinson disease rat model. Methods: Seven unilaterally 6-hydroxydopamine-lesioned rats (dopaminergic denervation [DD] range, 36%-94%) were injected with 3.7 MBq/100 g of body weight and tracer masses ranging from 93.8 to 0.0041 mg/100 g of body weight. We evaluated the maximum available transporter density and the in vivo (apparent) ligand-transporter dissociation constant (B max and K app d , respectively) with an in vivo Scatchard method using several modeling approaches and estimated the transporter occupancy as a function of the amount of tracer injected and tracer specific activity (SA). Results: Strong evidence of different nonspecific binding in the striatal region, compared with the reference region, leading to bias in the estimate of DD severity was found. One percent transporter occupancy was reached with 0.14 mg of tracer/100 g of body weight, corresponding to an SA of 5.7 kBq/pmol for the given radioactivity dose, and 10% occupancy was reached at 1.5 mg of tracer/100 g of body weight, corresponding to an SA of 0.57 kBq/ pmol. The 6-hydroxydopamine lesion affected B max (control, 402 6 94 pmol/mL; lesioned, 117 6 120 pmol/mL; P 5 0.003) but not K app d
Toxi n-induced and transgenic rodent models of human disease are becoming increasingly more relevant to the investigation of specific disease mechanisms and pathogenesis and the evaluation of potential effects of novel treatment strategies. Although potentially quite informative, animal models must be validated against human disease. Noninvasive molecular imaging, such as PET, can aid by providing common investigative protocols in which biologically relevant outcomes can be directly compared. To ensure a meaningful comparison, rodent brain imaging must be accurately characterized to avoid potential methodologic confounding effects due to the smaller size of the rodent brain and potential differences in tracer metabolism and binding. Although dedicated small-animal scanners, capable of approximately (1.5 mm) 3 resolution, partially address the imaging resolution limitations, a stricter limit on the amount of administered tracer must be used to avoid pharmacologic effects. Given that the injected tracer radioactivity dose needs to be maintained sufficiently high to obtain statistically meaningful data, the tracer must be produced at a specific activity (SA) high enough to ensure negligible tracer mass effect. This limit, together with potential differences in tracer binding and metabolism, are tracerand species-dependent and must be characterized for each case separately.
Multitracer PET of the dopaminergic system has been performed for decades on human subjects with Parkinson disease, a debilitating condition of still unknown etiology, affecting approximately 300/100,000 of the general population (1) and characterized by dopaminergic neuronal degeneration. There is ample evidence that the membrane dopamine transporter (DAT) is affected by disease. The nature of the implication of DAT in Parkinson disease is controversial: it could contribute to the origin of the disease (2) (3) (4) (5) , or it could delay the onset of clinical symptoms by compensatory downregulation (6) . It might also be functionally associated with an increased risk of occurrence of treatmentrelated motor and psychiatric complications (7) (8) (9) . DAT has also been used as a surrogate marker of treatment efficacy, with inconsistent outcomes (10) (11) (12) . These unresolved questions render DAT an important target of investigation. A radiotracer commonly used to evaluate DAT binding availability in humans is 11 C-methylphenidate. We thus undertook a characterization of DAT imaging with 11 C-methylphenidate in the commonly used 6-hydroxydopamine rat model of Parkinson disease (10, 13, 14) . We estimated the typical maximum available transporter density and in vivo (apparent) ligand-transporter dissociation constant (B max and K app d , respectively) and their dependence on the severity of dopaminergic denervation (DD). We also evaluated the consistency between different modeling approaches to the determination of B max and K app d and explored the validity of the assumption that the amount of nonspecific binding is consistent between the target and reference region, a requisite condition to obtain unbiased estimates of the tissue input-derived nondisplaceable binding potential (BP ND 5 B max /K d · f 2 , where f 2 is the fraction of tracer that is freely dissolved in tissue) (15) . Finally, useful limits on the tracer SA or amount necessary to ensure lack of tracer pharmacologic effects were determined by investigating transporter occupancy as a function of amount of tracer administered and SA. (17) . For the Logan approach, the term containing the reference tissue clearance rate constant k 2 9 was neglected (18) and the Logan slope was calculated from 30 to 60 min after tracer injection. The use of the cerebellar tracer concentration to obtain an estimate of F is based on the assumption that the concentration of free and nonspecifically bound tracer in the target (the striatum) and reference region (the cerebellum) is the same. A violation of this assumption would manifest itself through the need to introduce an extra term to account for the difference; such a term (NS) is introduced in Equation 2 (19) . The group analysis is also based on the assumption that the variability of B max and K app d between animals is negligible compared with the tracer mass effect: this analysis was thus applied only to the data obtained from the control striatum of each rat. Potential lesion-induced compensatory changes on the control side would be minimal and were considered irrelevant for the purpose of this study. Eq. 7
MATERIALS AND METHODS

Group
The least biased estimate of DD was deemed to be that obtained with (B/F) e estimated from the high-SA scans, since it best approximates the true BP ND . An estimate of DD was also obtained as:
Eq. 8
If indeed 6-hydroxydopamine lesioning results in a change in B max and not K app d , DD estimated from (B/F) e and B max should agree, assuming that reliable estimates of B max can be obtained.
Occupancy
Transporter occupancy was defined as Occ 5 1 2 (B/F) e SA / (B/F) e highSA (15) and as Occ 2NS 5 1 2 ((B/F) e SA 2 NS)/(1 2 (B/F) e highSA 2 NS), was plotted as a function of log 10 (1/SA), and was fitted to the expression Occ
is the apparent dissociation constant expressed in units of 1/SA (pmol/kBq). Considering that each rat was injected with approximately 3.7 MBq/100 g, 1/SA is a measure of the total mass of tracer injected per unit body weight. To visualize the latter relation, Occ was also plotted as a function of the injected tracer amount (mg) normalized to 100 g of animal weight (amount 5 mass of injected tracer amount (mg) per 100 g of animal weight) and fitted to the expression Occ
is the apparent dissociation constant expressed in units of micrograms of injected tracer/100 g of animal weight. The occupancy curves were determined only for the control side of the striatum, since in the lesioned animals occupancy values were found to be in some cases too noisy, thus leading to unrealistic occupancy values (see "Results").
Chemistry, Stock Solution Preparation, and SA Adjustment and Measurement 11 C-methylphenidate was synthesized using a published method (21) and provided greater than 95% radiochemically pure d-threo-11 Cmethylphenidate with SA of greater than 55.5 kBq/pmol at the end of synthesis. A known amount of 11 C-methylphenidate, ranging from 12.5 to 125 mg, was added to the high-SA 11 C-methylphenidate sample using the stock solution (supplemental material, available online at http://jnm.snmjournals.org).
Animals
Seven male Sprague-Dawley rats (604 6 39 g at the time of scanning) unilaterally lesioned with 6-hydroxydopamine were included in the study. Lesioning was performed as previously described (22) . Briefly, the animals were anesthetized with isoflurane and placed in the stereotactic headholder with the skull flat between lambda and bregma. A 2% solution of 6-hydroxydopamine hydrobromide was infused at 2 sites (2 animals) along the medial forebrain bundle. Five animals had only 1 infusion of the 6-hydroxydopamine solution at 1 site so as to achieve a varying degree of denervation. Approximately 30 min before the 6-hydroxydopamine infusion, the animals were given desipramine (25 mg/kg intraperitoneally) to protect noradrenergic fibers (23) . The animals were allowed at least 3-4 wk recovery before undergoing the PET studies.
Scanning
The rats were anesthetized and maintained with a 2% isoflorane/O 2 gas mixture. All studies were performed on a Siemens/ Concorde microPET Focus 120 (24) . Each rat was positioned in a stereotactic headholder mounted to the scanner bed, allowing accurate repositioning of the animal within the ear bars and the mouthpiece. After a 6-min transmission scan with a 57 Co source, a 61-min-long dynamically acquired emission scan was performed starting at injection (supplemental material). A 3.7-MBq bolus of tracer per 100 g of body weight was administered, with SA ranging from 0.009 to 191 kBq/pmol, corresponding to a tracer mass ranging from 93.8 to 0.0041 mg/100 g of body weight as detailed in Table 1 .
To limit the amount of time the rats were kept under anesthesia, each rat underwent at most 2 scans per day, for which the 2 tracer injections were administered 120 min apart. The higher-SA scan was always performed first to minimize potential residual tracer occupancy effects. All procedures were approved by the University of British Columbia Animal Care Committee.
Data Analysis
The high-SA tracer scan was used as a reference image for analysis of the medium-and low-SA scans. First, a brain atlas (25) was manually coregistered to the brain area in the high-SA scans summed over data from the entire dynamic sequence (supplemental material). Using the coregistered atlas for guidance, we placed a rectangular (2.6 · 3.5) mm 2 region of interest on each striatum on 3 consecutive transaxial planes (plane thickness, 0.796 mm) and a (6.9 · 2.6) mm 2 region of interest on the cerebellum. The regions of interest were then replicated on each frame of the dynamic sequence for the extraction of a time-activity curve. Each medium-and low-SA scan was coregistered to the high-SA scan. The regions of interest defined on the high-SA scan were carried over to the coregistered medium-and low-SA scans for timeactivity curve extraction. (Table 2) indicates that more consistent results are obtained when 4 points are included in the fit than when 3 are included. Interestingly, whereas inclusion of the NS term minimizes the dependence of the B max and K app d estimates on the range of F on average, it also increases the coefficient of variation. This is likely due to the fact that a common value of NS was used for all rats. NS could not be de- Results for the lesioned side are shown in Figure 3 and detailed in Supplemental Table 1 . The fits to the data became increasingly less reliable with higher denervation severity; for example, for rats 4 and 5 a reliable estimate for K app d
RESULTS
Comparison of (B/
could not be obtained with any method, in contrast to the data from the control side, for which the fitting method did not influence the results. The highest number of plausible fits was obtained when tracer amounts were limited to less than 2.5 mg/100 g, that is, when only 3 points were included in the fit and NS was subtracted (Eq. 5). In several cases, (B/F) e did not appear to change as a function of SA, indicating apparent lack of displacement (Fig. 3) . Figure 4 shows the DD estimated according to Equations 6 and 7. The DD estimate without subtraction of the NS term exhibits a clear dependence on tracer SA, especially at higher DD levels. Such dependence decreases with subtraction of the NS term. This finding is consistent with a difference in nondisplaceable binding between the striatum and reference region, which becomes increasingly more relevant for low (B/F) e values (low amount of specific binding).
DD Severity Estimate
An excellent correlation between DD evaluated from the (B/F) e with NS subtracted (Eq. 7) (range [36%-94%]) and using the B max values as estimated from the linear 3-point Scatchard fits (Eqs. 5 and 8) was found, as shown in Figure  5 , indicating that reasonable values were obtained for B max even for the lesioned side when the NS term was subtracted and the range of F limited. Table 1 ). Although there was a highly significant difference between the control and lesioned sides for B max (control, 402 6 94 pmol/mL; lesioned, 117 6 120 pmol/mL; P 5 0.003), K app d did not change as a function of 6-hydroxydopamine lesion (control, 331 6 63 pmol/mL; lesioned, 362 6 119 pmol/mL; P 5 0.63). 
Occupancy
Occupancy curves without and with the NS term subtracted are shown in Figure 6 . The curves are similar, with a higher occupancy being estimated when the NS term is subtracted. Amounts of tracers and SA required to reach 1% and 10% transporter occupancy are detailed in Table 3 .
DISCUSSION
Several observations can be derived from the results. Of immediate practical relevance is the finding that relatively large 11 C-methylphenidate amounts are required to induce noticeable transporter occupancy. For example, 10% occupancy is reached with approximately 1.5 mg of 11 Cmethylphenidate/100 g of body weight, whereas only 0.31 mg of the vesicular monoamine transporter 2 tracer 11 C-dyhydrotetrabenazine/100 g of body weight leads to the same fraction of vesicular monoamine transporter 2 occupancy (26). 11 C-methylphenidate can thus be produced with less stringent constraints on its SA, or conversely, a higher radioactivity dose can be injected, if a better statistical quality of the data is required.
Of more theoretic importance are the results obtained from comparison of the modeling approaches to the determination of (B/F) e , B, B max , and K app d . Although the Logan and SRTM methods yielded consistent results for (B/ F) e , the estimate of the bound tracer B exhibited a clear dependence on the method used to calculate it. When B was estimated directly from subtraction of the time-activity curve values in the striatum and cerebellum averaged over the last 30 min of data acquisition, both B max and K app d were larger than when B was estimated from the SRTM (or Logan) method-derived estimate of (B/F) e and F from the cerebellar time-activity curve. This finding likely reflects a residual time dependence of the bound B and free F tracer concentration as a consequence of the bolus injection method-in contrast to the equilibrium assumption of the MLCTA method-and a difference in the nonspecifically bound tracer concentration between the 2 regions. Taken together, these observations suggest that B estimated from (B/F) e likely provides a more accurate (although not perfect) estimate of the bound tracer concentration; (B/F) e evaluated with the modeling approaches used is not affected by the tracer administration method, and the impact of a different concentration of the nonspecifically bound tracer between the 2 regions is minimized. The bolusplus-constant-infusion method might provide a more accurate estimate of the equilibrium value of F; however, bolus-plus-constant-infusion methods of tracer administration tend to be methodologically more complex and susceptible to a regional variability of the optimal ratio between the amount of tracer administered as a bolus and that administered as a constant infusion.
Possibly the most important outcome of the study is strong evidence of a difference between the nonspecifically bound tracer concentration in the striatum and reference region. An attempt was made to fit the Scatchard plots with a 2-binding-site model, but no meaningful results were obtained, indicating that if a second type of binding site exists, the affinity must be so low that it cannot be reliably measured with the present data. Of course, it is possible that the high doses of 11 C-methylphenidate, administered when the ligand was produced at very low SA, might introduce secondary pharmacologic effects, which could confound the MLCTA and occupancy analyses (27) . Interestingly, in both rat and mouse groups, derived B max and K app d values for 11 C-raclopride (a D 2 -type receptor antagonist) are better defined using an expression explicitly accounting for an NS term (19, 28) .
To test this hypothesis, we revisited the comparison between DD severity measured in vivo by 11 C-methylphenidate PET and by in vitro 3 H-WIN 35,428 autoradiography performed on extracted brain slices of the same animals. The original comparison was performed on a group of 16 rats and was part of a previously published study (22) in which all the scans were obtained with 11 C-methylphenidate produced at an SA high enough to ensure negligible transporter occupancy (.40.7 kBq/pmol). PET-derived DD for those data was now estimated without and with subtraction of the NS term, with value fixed at the currently estimated 0.14. When the NS term is subtracted from the BP ND , the correlation between the PET-and autoradiography-derived DD values virtually follows the line of identity, whereas the PET-derived DD values underestimate the autoradiography-derived DD values without subtraction of the NS term (Fig. 7) . This finding argues against the supposition that the NS term might arise as a consequence of a methodologic confound due to a pharmacologic effect of larger amounts of 11 C-methylphenidate and suggests that it is indeed a characteristic of 11 C-methylphenidate binding. The origin and exact interpretation of such a term is at present speculative, and further comparisons to ex vivo or in vitro data must be performed to correctly identify its meaning. Further studies at very low SA are also required to precisely determine its value.
Despite these limitations, and the admitted uncertainty about the exact interpretation and value of the NS term, we deemed that a more informative comparison between the estimated B max and K app d of the control and 6-hydroxydopamine-lesioned side is obtained when the NS term is explicitly considered. Although a significant difference was found for B max between the lesioned and control sides, no such difference was observed for K app d , indicating that the decreased value of BP ND as estimated from the high SA (B/F) e on the lesion side indicates a reduction in transporter density, rather than being reflective of competitive endogenous ligand changes. The finding that chronic degeneration of the nigral dopamine terminals affects primarily B max is consistent with studies using other pre-and postsynaptic ligands in both human and nonhuman primates with raclopride (29, 30) or in rodents with 11 C-dyhydrotetrabenazine (26) . This might in turn suggest that changes in K app d may occur mostly as a mechanism to adapt rapidly to acute changes in the receptor or transporter environment.
Finally, it is of interest to compare the behavior of 11 Cmethylphenidate DAT binding with that of other tracers used to investigate the dopaminergic system in rats. Similar occupancy studies performed with 11 C-dyhydrotetrabenazine on unilaterally 6-hydroxydopamine-lesioned rats demonstrated very different characteristics: no dependence of DD severity estimate on tracer SA and excellent linearity of the Scatchard plots over a wide range of free (or bound) tracer concentrations, thus presenting no evidence of a difference in the concentration of the nonspecifically bound tracer between the striatum and reference region (26) . Because the impact of the NS term is particularly relevant to a situation of high denervation severity, care must be taken when comparing outcomes of multitracer studies in such a situation. The impact of these findings on human DAT imaging with 11 C-methylphenidate cannot be readily assessed with these results. Interspecies differences and the nature of the neurotoxin 6-hydroxydopamine-induced lesion could invalidate a direct extrapolation of these results to the human case. Nevertheless, these data might suggest the need for caution in interpreting 11 C-methylphenidate DAT binding in extreme disease situations. analysis performed with the control striatum data obtained from scans of rats injected with 11 C-methylphenidate produced at different specific activities strongly suggested a difference in nonspecific binding between the striatum and reference region. The estimates of B max and K app d were found to be dependent on the method of analysis used, especially for the lesioned side, but were more consistent when the difference in nonspecific binding was explicitly accounted for. Although the origin and exact interpretation of what appears to be additional nonspecific 11 C-methylphenidate binding in the striatum, compared with the cerebellum, was not identified, these data indicate that caution is required in comparing binding of different dopaminergic tracers in a situation of high DD severity.
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